If you follow peptides online, 2026 sounds like a gold rush is coming. The reality is more nuanced — and understanding it protects you from both bad products and bad actors. Here's the honest version.
What a provider can prescribe today
A short list of peptides is legally available right now through licensed telehealth working with compounding pharmacies. These include compounds like sermorelin, NAD+, and glutathione — available because they sit in the categories that allow licensed compounding. A provider decides whether any of them is appropriate for you based on your history and labs; nothing here is sold off a shelf.
What's still under review
The headline names — BPC-157, TB-500, CJC-1295/Ipamorelin, and others — are not currently available for sale. In April 2026, federal health authorities moved a group of these peptides toward consideration for the pathway that would allow licensed compounding. A Pharmacy Compounding Advisory Committee (PCAC) review is scheduled for July 23–24, 2026.
Why the "research only" market is a trap
While the legal path develops, a gray market sells these same compounds labeled "research only" or "not for human use." That labeling is a legal fiction that protects the seller, not you. These products can be mislabeled, under-dosed, or contaminated, and they come with no provider, no monitoring, and no recourse. The entire point of supervised care is to remove that risk.
How to think about it
- If a peptide is available through a licensed provider and pharmacy today, that's the legitimate path.
- If it's "coming with the July ruling," treat that as a future possibility, not a current offer.
- If it's sold "research only" without a prescription, that's the gray market — and the risk is yours.